Investigational approaches to therapies for idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: In fibrosing diseases, scar tissue begins to replace normal tissue, causing tissue dysfunction. For instance, in lung fibrosis, foci of what resembles scar tissue form in the lungs, impeding the ability of patients to breathe. These conditions represent a significant source of morbidity and mortality. More than 150,000 people in the USA have some form of fibrotic lung disease, and the 5-year mortality rate for these diseases can be as high as 80%. Despite this large unmet medical need, there are no FDA-approved therapies. Although our understanding of the causes and the biology of fibrosing diseases remains relatively poor, we have made impressive advances in identifying the major cell populations and many biochemical mediators that can drive this process. As a result, novel therapeutics are being developed based upon these discoveries. AREAS COVERED IN THIS REVIEW: This review examines the experimental therapies currently under investigation as of late 2009 for a major class of lung fibrosis called idiopathic pulmonary fibrosis (IPF). WHAT THE READER WILL GAIN: The reader will gain an overview of current experimental therapies for IPF. TAKE HOME MESSAGE: With the recent approval of Pirfenidone in Japan for use in IPF, and a rich pipeline of experimental therapies in various stages of clinical development, the future looks bright for new treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“[82]; Scleroderma with interstitial”
Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites
Abe, R., Donnelly, S. C., Peng, T., Bucala, R., & Metz, C. N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7556 · Cited by 967 · cited 1×
“In addition to the proliferation of fibroblasts at the exposed surface of a wound, circulating monocytes can enter the wound and differentiate into fibroblast-like cells called fibrocytes [1-5].”
BackgroundHigh-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964 · cited 4×
“DLCO also deteriorated less in those given NAC (relative difference: 24%, p = 0.003).”
BackgroundInfluentialN-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency
Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.005 · Cited by 721 · cited 1×
“NAC increases levels of the antioxidant glutathione [46], which can protect tissues from oxidant-induced damage, a potential side effect of the common use of azathioprine in IPF patients.”
BackgroundKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531 · cited 1×
“Idiopathic pulmonary fibrosis does not appear to involve classical inflammation such as occurs in rheumatic diseases like rheumatoid arthritis, and formal clinical trials or general clinical impressions and experience indicate that broadspectrum anti-inflammatory drugs, immunosuppressants, and immunomodulators such as…”
BackgroundImatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373 · cited 1×
“An initial Phase 2 clinical trial was conducted in 120 IPF patients comparing 600 mg of imatinib mesylate to placebo, but the drug failed to improve survival or changes in forced vital capacity (FVC) [59].”
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370 · cited 1×
“An initial randomized, prospective, double-blind Phase II clinical trial was conducted in 88 IPF patients comparing 25 mg twice weekly subcutaneous etanercept with placebo [62].”
MethodChua, F., Gauldie, J., & Laurent, G. J. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0062tr · Cited by 305
Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P
Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., & Gomer, R. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4035 · Cited by 230 · cited 1×
“In vitro and in vivo data in preclinical models demonstrate that SAP is broadly effective at blocking the fibrotic process downstream of multiple types of injury and under multiple cytokine stimulation conditions [77-81].”
BackgroundSelf-citationSildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis
Jackson, R. M., Glassberg, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Gómez-Marín, O. (2010) · Lung · doi:10.1007/s00408-009-9209-8 · Cited by 92 · cited 1×
“A second small Phase II study by independent investigators was recently reported which did not show a significant difference in exercise tolerance between sildenafil and placebo [51].”
Background
Cited by
Palmer, S. M., Snyder, L., Todd, J. L., Soule, B., Christian, R., Anstrom, K., Luo, Y., Gagnon, R., & Rosen, G. (2018) · Chest · doi:10.1016/j.chest.2018.08.1058 · Cited by 202
Gill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
Sivaraman, L., Gill, M., Nelson, D. M., & Chadwick, K. D. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115846 · Cited by 17
Fan, L., Shetty, R. S., Dao, H. M., Balnadupete, A., Somasundram, B., Bhagavath, A. K., Kongara, A., Tang, H., Citrin, D. E., Williams, R. O., et al. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00295.2024 · Cited by 3
Metadata
- Authors
- Gomer, R. H., & Lupher, M. L.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2010-05-06
- Volume
- 19
- Issue
- 6
- Pages
- 737-745
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2105748632
- Cited by
- 29
- References
- 11
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.